keyword
MENU ▼
Read by QxMD icon Read
search

Bevacizumab glioblastoma

keyword
https://www.readbyqxmd.com/read/29221983/medication-related-osteonecrosis-of-the-jaws-associated-with-targeted-therapy-as-monotherapy-and-in-combination-with-antiresorptives-a-report-of-7-cases-from-the-copenhagen-cohort
#1
Hoda Abel Mahedi Mohamed, Charlotte Emilie Nor Nielsen, Morten Schiodt
OBJECTIVE: The aim of this study was to report cases of medication-related osteonecrosis of the jaws (MRONJ) associated with targeted therapy (TT) with or without concomitant antiresorptive treatment, among the Copenhagen ONJ cohort, which includes all consecutive cases of MRONJ seen in Copenhagen. STUDY DESIGN: We retrospectively studied the treatment of 204 consecutive patients with MRONJ, seen between January 2010 and May 2016, to identify those associated with TT...
November 6, 2017: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
https://www.readbyqxmd.com/read/29217134/reirradiation-with-concurrent-bevacizumab-for-recurrent-high-grade-gliomas-in-adult-patients
#2
A Schernberg, F Dhermain, S Ammari, S N Dumont, J Domont, A Patrikidou, J Pallud, É Dezamis, É Deutsch, G Louvel
PURPOSE: To analyse feasibility, prognostic factors and patterns of recurrence after concurrent reirradiation and bevacizumab for recurrent high-grade gliomas. PATIENTS AND METHODS: Between 2009 and 2015, 35 patients (median 57-year-old; 21 men, 14 women) with WHO grade III (n=11) or grade IV (n=24) gliomas were included in this retrospective and consecutive single-centre study. All patients received bevacizumab (median number of treatments: 12) concomitant with reirradiation (median dose: 45Gy, median number of fractions: 18) for recurrence with median 22 months (range: 5...
December 4, 2017: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
https://www.readbyqxmd.com/read/29207684/recurrent-glioma-clinical-trial-checkmate-143-the-game-is-not-over-yet
#3
REVIEW
Anna C Filley, Mario Henriquez, Mahua Dey
Glioblastoma (GBM) is the most common, and aggressive, primary brain tumor in adults. With a median patient survival of less than two years, GBM represents one of the biggest therapeutic challenges of the modern era. Even with the best available treatment, recurrence rates are nearly 100% and therapeutic options at the time of relapse are extremely limited. Nivolumab, an anti-programmed cell death-1 (PD-1) monoclonal antibody, has provided significant clinical benefits in the treatment of various advanced cancers and represented a promising therapy for primary and recurrent GBM...
October 31, 2017: Oncotarget
https://www.readbyqxmd.com/read/29200110/high-grade-gliomas
#4
Lakshmi Nayak, David A Reardon
PURPOSE OF REVIEW: This article reviews the standard treatment for high-grade gliomas, with a focus on promising new strategies and response assessment. RECENT FINDINGS: The new World Health Organization (WHO) classification of central nervous system tumors classifies high-grade gliomas based on molecular markers that are of prognostic and therapeutic significance. The addition of chemotherapy, specifically procarbazine, CCNU (lomustine), and vincristine, to radiation in newly diagnosed 1p/19q codeleted anaplastic oligodendrogliomas doubled overall survival...
December 2017: Continuum: Lifelong Learning in Neurology
https://www.readbyqxmd.com/read/29183864/surgery-for-recurrent-high-grade-glioma-after-treatment-with-bevacizumab
#5
Deborah T Blumenthal, Andrew A Kanner, Orna Aizenstein, Emanuela Cagnano, Ariel Greenberg, Dov Hershkovitz, Zvi Ram, Felix Bokstein
BACKGROUND: Bevacizumab (BVZ) is an FDA-approved anti-angiogenic agent used for treatment of recurrent glioblastoma. Complications related to impaired healing may adversely affect patients resected for recurrent high-grade glioma (HGG) following treatment with BVZ. OBJECTIVE: To examine the complication rate, outcome, and tumor vasculature in patients resected for recurrent HGG following treatment with BVZ. METHODS: Data were reviewed retrospectively from patients undergoing surgery for recurrent HGG following treatment with BVZ...
November 25, 2017: World Neurosurgery
https://www.readbyqxmd.com/read/29171805/erratum-bevacizumab-and-irinotecan-therapy-in-glioblastoma-multiforme-a-series-of-13-cases
#6
Gillian Shasby
No abstract text is available yet for this article.
November 24, 2017: Journal of Neurosurgery
https://www.readbyqxmd.com/read/29171803/letter-to-the-editor-puzzling-posology-was-the-bevacizumab-regimen-in-recurrent-glioblastoma-misreported
#7
David Neil
No abstract text is available yet for this article.
November 24, 2017: Journal of Neurosurgery
https://www.readbyqxmd.com/read/29163521/cd4-and-perivascular-foxp3-t-cells-in-glioma-correlate-with-angiogenesis-and-tumor-progression
#8
Luyan Mu, Changlin Yang, Qiang Gao, Yu Long, Haitao Ge, Gabriel DeLeon, Linchun Jin, Yifan Emily Chang, Elias J Sayour, Jingjing Ji, Jie Jiang, Paul S Kubilis, Jiping Qi, Yunhe Gu, Jiabin Wang, Yuwen Song, Duane A Mitchell, Zhiguo Lin, Jianping Huang
Background: Angiogenesis and immune cell infiltration are key features of gliomas and their manipulation of the microenvironment, but their prognostic significance remains indeterminate. We evaluate the interconnection between tumor-infiltrating lymphocyte (TIL) and tumor blood-vasculatures in the context of glioma progression. Methods: Paired tumor tissues of 44 patients from three tumor-recurrent groups: diffuse astrocytomas (DA) recurred as DA, DA recurred as glioblastomas (GBM), and GBM recurred as GBM were evaluated by genetic analysis, immunohistochemistry for tumor blood vessel density, TIL subsets, and clinical outcomes...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/29156610/bevacizumab-for-patients-with-recurrent-multifocal-glioblastomas
#9
Michael C Burger, Stella Breuer, Hans C Cieplik, Patrick N Harter, Kea Franz, Oliver Bähr, Joachim P Steinbach
In patients with glioblastoma, antiangiogenic therapy with bevacizumab (BEV) has been shown to improve progression-free survival (PFS), but not overall survival (OS). Especially in patients with an unusual infiltrative phenotype as seen in multifocal glioblastoma, the use of BEV therapy is still more controversial. Therefore, we prepared a retrospective case series with 16 patients suffering from a multifocal glioblastoma treated with BEV. We compared these patients to a matched control cohort of 16 patients suffering from glioblastoma with a single lesion treated with BEV...
November 20, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29152068/age-associated-and-therapy-induced-alterations-in-the-cellular-microenvironment-of-experimental-gliomas
#10
Hannah Schneider, Birthe Lohmann, Hans-Georg Wirsching, Kathy Hasenbach, Elisabeth J Rushing, Karl Frei, Martin Pruschy, Ghazaleh Tabatabai, Michael Weller
The poor prognosis associated with advanced age in patients with glioblastoma remains poorly understood. Glioblastoma in the elderly has been particularly associated with vascular endothelial growth factor (VEGF)-dependent angiogenesis, and early uncontrolled studies suggested that the anti-angiogenic agent bevacizumab (BEV), an antibody to VEGF, might be preferentially active in this patient population. Accordingly, we explored host age-dependent differences in survival and benefit from radiotherapy (RT) or BEV in syngeneic mouse glioma models...
October 20, 2017: Oncotarget
https://www.readbyqxmd.com/read/29151389/bevacizumab-in-recurrent-high-grade-gliomas-a-canadian-retrospective-study
#11
Mary Jane Lim Fat, Catherine Maurice, Manjula Maganti, Warren P Mason
BACKGROUND: Bevacizumab has been used in recurrent glioblastoma (rGBM) since 2010 in Canada. Given its cost, potential toxicities, and unclear efficacy, further studies are required to better define suitable candidates for therapy. METHODS: A single-center retrospective review of patients started on bevacizumab for rGBM from 2012 to 2015 was performed. Patient demographics, tumor characteristics, treatment regimen, and dates of clinical progression and death were collected...
November 20, 2017: Canadian Journal of Neurological Sciences. le Journal Canadien des Sciences Neurologiques
https://www.readbyqxmd.com/read/29141164/lomustine-and-bevacizumab-in-progressive-glioblastoma
#12
RANDOMIZED CONTROLLED TRIAL
Wolfgang Wick, Thierry Gorlia, Martin Bendszus, Martin Taphoorn, Felix Sahm, Inga Harting, Alba A Brandes, Walter Taal, Julien Domont, Ahmed Idbaih, Mario Campone, Paul M Clement, Roger Stupp, Michel Fabbro, Emilie Le Rhun, Francois Dubois, Michael Weller, Andreas von Deimling, Vassilis Golfinopoulos, Jacoline C Bromberg, Michael Platten, Martin Klein, Martin J van den Bent
BACKGROUND: Bevacizumab is approved for the treatment of patients with progressive glioblastoma on the basis of uncontrolled data. Data from a phase 2 trial suggested that the addition of bevacizumab to lomustine might improve overall survival as compared with monotherapies. We sought to determine whether the combination would result in longer overall survival than lomustine alone among patients at first progression of glioblastoma. METHODS: We randomly assigned patients with progression after chemoradiation in a 2:1 ratio to receive lomustine plus bevacizumab (combination group, 288 patients) or lomustine alone (monotherapy group, 149 patients)...
November 16, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29133513/phase-ii-study-of-bevacizumab-and-vorinostat-for-patients-with-recurrent-world-health-organization-grade-4-malignant-glioma
#13
Ashley Ghiaseddin, David Reardon, Woody Massey, Alex Mannerino, Eric S Lipp, James E Herndon, Frances McSherry, Annick Desjardins, Dina Randazzo, Henry S Friedman, Katherine B Peters
LESSONS LEARNED: Combination regimen with bevacizumab (BEV) and vorinostat is well tolerated in patients with recurrent glioblastoma.Treatment of recurrent glioblastoma remains challenging as this study and others attempt to improve progression-free survival and overall survival with BEV-containing regimens. BACKGROUND: Recurrent glioblastoma (GBM; World Health Organization grade 4) continues to have a very poor prognosis. Bevacizumab (BEV) has been shown to improve progression-free survival (PFS) in recurrent GBM and is approved by the U...
November 13, 2017: Oncologist
https://www.readbyqxmd.com/read/29121274/quality-of-life-in-the-glarius-trial-randomizing-bevacizumab-irinotecan-versus-temozolomide-in-newly-diagnosed-mgmt-nonmethylated-glioblastoma
#14
Niklas Schäfer, Martin Proescholdt, Joachim P Steinbach, Astrid Weyerbrock, Peter Hau, Oliver Grauer, Roland Goldbrunner, Franziska Friedrich, Veit Rohde, Florian Ringel, Uwe Schlegel, Michael Sabel, Michael W Ronellenfitsch, Martin Uhl, Stefan Grau, Mathias Hänel, Oliver Schnell, Dietmar Krex, Peter Vajkoczy, Ghazaleh Tabatabai, Frederic Mack, Christina Schaub, Theophilos Tzaridis, Michael Nießen, Sied Kebir, Barbara Leutgeb, Horst Urbach, Claus Belka, Walter Stummer, Martin Glas, Ulrich Herrlinger
Background: The GLARIUS trial which investigated the efficacy of bevacizumab (BEV)/irinotecan (IRI) as compared to standard temozolomide (TMZ) in the first-line therapy of MGMT-nonmethylated glioblastoma showed that progression-free survival was significantly prolonged by BEV/IRI while overall survival was similar in both arms. The present report focusses on quality of life (QoL) and Karnofsky performance score (KPS) during the whole course of the disease. Patients and methods: Patients (n=170) received standard radiotherapy and were randomized (2:1) for BEV/IRI or standard TMZ...
November 7, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/29108308/a-phase-2-study-of-the-first-imipridone-onc201-a-selective-drd2-antagonist-for-oncology-administered-every-three-weeks-in-recurrent-glioblastoma
#15
Isabel Arrillaga-Romany, Andrew S Chi, Joshua E Allen, Wolfgang Oster, Patrick Y Wen, Tracy T Batchelor
ONC201 is an oral, small molecule selective antagonist of the G protein-coupled receptor DRD2 that causes p53-independent apoptosis in tumor cells via integrated stress response activation and Akt/ERK inactivation. We performed a Phase II study that enrolled 17 patients with recurrent, bevacizumab-naïve, IDH1/2 WT glioblastoma who received 625mg ONC201 every three weeks. Median OS was 41.6 weeks with OS6 of 71% and OS9 of 53%. Seven of 17 patients are alive. PFS6 was 11.8% with two patients remaining on study who continue to receive ONC201 for >12 months...
October 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29081442/glioblastoma-treatment-in-the-elderly
#16
Masaki Okada, Keisuke Miyake, Takashi Tamiya
Although current treatment advances prolong patient survival, treatment for glioblastoma (GBM) in the elderly has become an emerging issue. The definition of "elderly" differs across articles; GBM predominantly occurs at an age ≥65 years, and the prognosis worsens with increasing age. Regarding molecular markers, isocitrate dehydrogenase (IDH) mutations are less common in the elderly with GBM. Meanwhile, O(6)-methylguanine DNA methyltransferase (MGMT) promoter methylation has been identified in approximately half of patients with GBM...
October 30, 2017: Neurologia Medico-chirurgica
https://www.readbyqxmd.com/read/29075855/efficacy-of-depatuxizumab-mafodotin-abt-414-monotherapy-in-patients-with-egfr-amplified-recurrent-glioblastoma-results-from-a-multi-center-international-study
#17
Martin van den Bent, Hui K Gan, Andrew B Lassman, Priya Kumthekar, Ryan Merrell, Nicholas Butowski, Zarnie Lwin, Tom Mikkelsen, Louis B Nabors, Kyriakos P Papadopoulos, Marta Penas-Prado, John Simes, Helen Wheeler, Tobias Walbert, Andrew M Scott, Erica Gomez, Ho-Jin Lee, Lisa Roberts-Rapp, Hao Xiong, Earle Bain, Peter J Ansell, Kyle D Holen, David Maag, David A Reardon
PURPOSE: Patients with recurrent glioblastoma (rGBM) have a poor prognosis. Epidermal growth factor receptor (EGFR) gene amplification is present in ~ 50% of glioblastomas (GBMs). Depatuxizumab mafodotin (depatux-m), formerly ABT-414, is an antibody-drug conjugate that preferentially binds cells with EGFR amplification, is internalized and releases a potent antimicrotubule agent, monomethyl auristatin F (MMAF). Here we report the safety, pharmacokinetics, and efficacy of depatux-m monotherapy at the recommended Phase 2 dose (RPTD) in patients with EGFR-amplified, rGBM...
December 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29066764/aberrant-glioblastoma-neovascularization-patterns-and-their-correlation-with-dce-mri-derived-parameters-following-temozolomide-and-bevacizumab-treatment
#18
Wei Xue, Xuesong Du, Hao Wu, Heng Liu, Tian Xie, Haipeng Tong, Xiao Chen, Yu Guo, Weiguo Zhang
Glioblastoma (GBM) is a highly angiogenic malignancy, and its abundant, aberrant neovascularization is closely related to the proliferation and invasion of tumor cells. However, anti-angiogenesis combined with standard radio-/chemo-therapy produces little improvement in treatment outcomes. Determining the reason for treatment failure is pivotal for GBM treatment. Here, histopathological analysis and dynamic contrast-enhanced MRI (DCE-MRI) were used to explore the effects of temozolomide (TMZ) and bevacizumab (BEV) on GBM neovascularization patterns in an orthotopic U87MG mouse model at 1, 3 and 6 days after treatment...
October 24, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29059154/fibroblast-growth-factor-13-regulates-glioma-cell-invasion-and-is-important-for-bevacizumab-induced-glioma-invasion
#19
Y Otani, T Ichikawa, K Kurozumi, S Inoue, J Ishida, T Oka, T Shimizu, Y Tomita, Y Hattori, A Uneda, Y Matsumoto, H Michiue, I Date
Glioblastoma has the poorest prognosis, and is characterized by excessive invasion and angiogenesis. To determine the invasive mechanisms, we previously used two glioma cell lines (J3T-1 and J3T-2) with different invasive phenotypes. The J3T-1 showed abundant angiogenesis and tumor cell invasion around neovasculature, while J3T-2 showed diffuse cell infiltration into surrounding healthy parenchyma. Microarray analyses were used to identify invasion-related genes in J3T-2 cells, and the expressed genes and their intracellular and intratumoral distribution patterns were evaluated in J3T-2 cell lines, human glioma cell lines, human glioblastoma stem cells and human glioblastoma specimens...
October 23, 2017: Oncogene
https://www.readbyqxmd.com/read/29034406/correction-to-phase-ii-study-of-bi-weekly-temozolomide-plus-bevacizumab-for-adult-patients-with-recurrent-glioblastoma
#20
Michael A Badruddoja, Marjorie Pazzi, Abhay Sanan, Kurt Schroeder, Kevin Kuzma, Thomas Norton, Thomas Scully, Daruka Mahadevan, Michael Malek Ahmadi
No abstract text is available yet for this article.
October 16, 2017: Cancer Chemotherapy and Pharmacology
keyword
keyword
80321
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"